InsidersTradesSigma
Track the OptimizeRx Corp share price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, OptimizeRx Corp has published 188 reports. Market capitalisation: €113.5m. The latest transaction was reported on 24 August 2026 (Retenue fiscale). Among the most active insiders: Silvestro Stephen L. All data is accessible without an account.
188
Insider Decl.
n/a
Thresholds
€3m
8 ops.
Buy Volume
€12m
31 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate OptimizeRx Corp Strong Buy (bullish), based on 5 analysts. Average price target: US$12.40.
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 8,943 of 29,062 companies
61.1
score / 100
Value65
Quality57
FCF yld12%
Earn yld3.4%
EV/EBITDA10.6x
ROE3.7%
Gross mgn67%
Net mgn4.7%
Debt/EBITDA1.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 August 2026
Declarations188 total
1,243 shares@ US$7.71Common StockSEC:0001628280-26-058584:0
57,600 shares0Common StockSEC:0001628280-26-058672:0
1,020 shares@ US$7.71Common StockSEC:0001628280-26-058589:0
57,600 shares0Common StockSEC:0001628280-26-058670:0
1,529 shares@ US$7.71Common StockSEC:0001628280-26-058586:0
57,600 shares0Common StockSEC:0001628280-26-058669:0
1,381 shares@ US$7.71Common StockSEC:0001628280-26-058583:0
1,737 shares@ US$7.71Common StockSEC:0001628280-26-058588:0
79,200 shares0Common StockSEC:0001628280-26-058673:0
4,000 sharesCommon StockSEC:0001628280-26-007972:0
5,237 shares0Common StockSEC:0001628280-25-058715:0
3,361 shares@ US$12.740.037% mcap1.7% of flowCommon StockSEC:0001628280-25-058799:0
4,079 shares@ US$12.7464.3% of flowCommon StockSEC:0001628280-25-058761:0
1,420 shares@ US$12.7428.8% of flowCommon StockSEC:0001628280-25-058770:0
4,051 shares@ US$12.7435.2% of flowCommon StockSEC:0001628280-25-058763:0
3,658 shares@ US$12.7425.7% of flowCommon StockSEC:0001628280-25-058758:0
3,361 shares@ US$12.743.0% of flowCommon StockSEC:0001628280-25-058768:0
5,237 shares0Common StockSEC:0001628280-25-058413:0
6,546 shares0Common StockSEC:0001628280-25-058412:0
3,928 shares0Common StockSEC:0001628280-25-058411:0
1,964 shares0Common StockSEC:0001628280-25-058408:0
289 shares@ US$13.5128.1% of flowCommon StockSEC:0001628280-25-058410:0
703 shares@ US$13.5132.1% of flowCommon StockSEC:0001628280-25-058409:0
712 shares@ US$14.03100.0% of flowCommon StockSEC:0001628280-25-057201:0
868 shares@ US$14.0360.8% of flowCommon StockSEC:0001628280-25-057199:0
25 of 188 declarations
关于 OptimizeRx Corp
OptimizeRx Corp. (Nasdaq: OPRX) 是一家在美国纳斯达克资本市场上市的美国医疗保健技术公司。对于法国、比利时和瑞士投资者而言，该公司处于医疗保健、软件和制药营销的交汇点。OptimizeRx 总部位于马萨诸塞州沃尔瑟姆，成立于 2006 年。其业务核心是一个技术平台，旨在帮助生命科学公司在受法规、数据隐私要求和工作流程整合影响的市场中，更好地接触和吸引医疗保健专业人员 (HCP) 和患者。([investors.optimizerx.com](https://investors.optimizerx.com/investor-relations)) OptimizeRx 最初围绕优惠券、共同支付援助和通过电子健康记录和电子处方工作流程提供的患者支持构建解决方案。随着时间的推移，该公司发展成为一个更广泛的数字健康和商业参与平台，结合了软件、数据、分析和有针对性的激活能力。收购 Medicx Health 扩大了该公司以消费者为中心的全渠道覆盖范围，并增强了其在单一隐私安全框架内连接 HCP 和直接面向消费者策略的能力。([optimizerx.com](https://www.optimizerx.com/about-us?utm_source=openai)) 如今，其主要业务线包括即时护理解决方案、工作流程内临床消息传递、受众激活、患者定位和隐私安全的全渠道营销。OptimizeRx 强调采用人工智能驱动的方法，旨在在护理时刻提供及时、相关的消息，并改善治疗的可及性和决策。从竞争角度来看，该公司通过其在 EHR/eRx 渠道中的嵌入式存在、其连接品牌与提供商和消费者的能力，以及其作为制药和更广泛生命科学预算的商业技术合作伙伴的定位来区分自己。([investors.optimizerx.com](https://investors.optimizerx.com/investor-relations)) 从地理上看，OptimizeRx 主要专注于美国，鉴于美国处方、医疗保健工作流程和医疗保健广告规则的结构，美国是其即时护理和制药参与模式的天然市场。该公司从其马萨诸塞州沃尔瑟姆总部为全国范围内的制药和生命科学客户提供服务。最近的通讯也指出网络持续扩张、战略续约和更深入的生态系统合作伙伴关系。([investors.optimizerx.com](https://investors.optimizerx.com/static-files/261cfad9-d91a-4bde-a9da-dfd3276f0075)) 最近的发展是建设性的。在 2025 年第二季度业绩中，OptimizeRx 报告收入增长 55% 至 $29.2 million，毛利润更高，恢复 GAAP 盈利，并提高了 2025 年全年指引。管理层还强调了更强的合同收入、持续的自由现金流生成和加速的债务偿还。对于投资者而言，关键的启示是盈利增长状况的改善，尽管该公司仍然面临客户集中度和制药营销商支出模式的风险。([investors.optimizerx.com](https://investors.optimizerx.com/static-files/261cfad9-d91a-4bde-a9da-dfd3276f0075))
